CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

被引：5
|
作者：
Messori, Andrea [1 ]
Damuzzo, Vera [2 ]
Leonardi, Luca [3 ]
Agnoletto, Laura [3 ]
Chiumente, Marco [3 ]
Mengato, Daniele [3 ]
机构：
[1] Reg Hlth Serv, HTA Unit, Via San Salvi 12, I-50135 Florence, Italy
[2] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Sch Hosp Pharm, Padua, Italy
[3] Italian Soc Clin Pharm & Therapeut, Sci Direct, Milan, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 07期
关键词：
TIME;
D O I：
10.1016/j.clml.2020.02.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：490 / 491
页数：2
相关论文
共 50 条
  • [31] The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Albanyan, Omar
    Chavez, Julio
    Munoz, Javier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [32] Single-Center Experience of Axicabtagene Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
    Melody, Megan
    Rahman, Zaid Abdel
    Ernesto, Ayala
    Gannon, Nicole
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Foran, James
    Dabaja, Mohamed Kharfan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S267 - S268
  • [33] The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
    Albanyan, Omar
    Chavez, Julio
    Munoz, Javier
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2022, 13
  • [34] CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
    Kinoshita, Hannah
    Bollard, Catherine M.
    Toner, Keri
    SEMINARS IN HEMATOLOGY, 2023, 60 (05) : 329 - 337
  • [35] Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
    Ernst, Moritz
    Oeser, Annika
    Besiroglu, Burcu
    Caro-Valenzuela, Julia
    Aziz, Mohamed Abd El
    Monsef, Ina
    Borchmann, Peter
    Estcourt, Lise J.
    Skoetz, Nicole
    Goldkuhle, Marius
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (09):
  • [36] Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany
    Skalt, Daniela
    Moertl, Bernhard
    von Bergwelt-Baildon, Michael
    Schmidt, Christian
    Schoel, Wolfgang
    Buecklein, Veit
    Weiglein, Tobias
    Dreyling, Martin
    Berger, Karin
    HEMASPHERE, 2022, 6 (07): : E736
  • [37] Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma
    Chihara, Dai
    Liao, Laura
    Tkacz, Joseph
    Franco, Anjali
    Lewing, Benjamin
    Kilgore, Karl M.
    Nastoupil, Loretta J.
    Chen, Lei
    BLOOD, 2023, 142 (12) : 1047 - 1055
  • [38] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [39] Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma
    Puig, Noemi
    Wang, Lisa
    Seshadri, Tara
    al-Farsi, Khalil
    Keating, Armand
    Crump, Michael
    Kuruvilla, John
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 507 - 513
  • [40] Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Ferrero, Simone
    Ghione, Paola
    Marabese, Alessandra
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ONCOLOGIST, 2016, 21 (09): : 1107 - 1112
12345